MY ACCOUNT | NEWSLETTER |

Dog walking-related injuries among adults presenting to U.S. emergency departments


Purpose 

Dog walking is a popular daily activity, yet information regarding its injury burden is limited. This study describes the epidemiology of injuries related to leash-dependent dog walking among adults presenting to U.S. emergency departments from 2001 to 2020.

Methods 

A retrospective analysis was performed using the National Electronic Injury Surveillance System (NEISS) database to identify adults (≥ 18 years) presenting to US emergency departments with leash-dependent dog walking-related injuries between 2001-2020. Outcomes included annual estimates of injury incidence, injury characteristics, and risk factors for sustaining a fracture or traumatic brain injury (TBI). Weighted estimates and 95% confidence intervals (CI) were generated using NEISS sample weights.

Results 

Between 2001 and 2020, an estimated 422,659 adults presented to US emergency departments with injuries related to leash-dependent dog walking. The annual incidence increased more than 4-fold during this period (n = 7282 vs n = 32,306, P < .001). Most patients were women (75%) and adults aged 40 to 64 years (47%), with a mean age of 53 ± 0.5 years. Patients commonly injured their upper extremity (51%) and were injured while falling when pulled or tripped by the leash (55%). The 3 most common injuries were finger fracture (6.9%), TBI (5.6%), and shoulder sprain/strain (5.1%). On multivariate analysis, fracture risk among dog walkers was higher in adults aged ≥65 years (odds ratio [OR] 2.1; 95%CI, 1.8-2.5) and women (OR 1.5, 95% CI, 1.3-1.7). Risk of TBI was also elevated among older dog walkers (OR 1.6, 95%CI, 1.3-2.0).

Conclusions 

Dog walking is associated with a considerable and rising injury burden. Dog owners should be informed of this injury potential and advised on risk-reduction strategies.

Maxson, Ridge et al. "Epidemiology of Dog Walking-Related Injuries Among Adults Presenting to U.S. Emergency Departments, 2001-2020." Medicine & Science in Sports & Exercise:10.1249/MSS.0000000000003184, April 14, 2023. DOI: 10.1249/MSS.0000000000003184 

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Gut Microbiome and Osteoarthritis: Insights From the Naturally Occurring Canine Model of Osteoarthritis

Like0
Dislike0

Velagliflozin, a once-daily, liquid, oral SGLT2 inhibitor, is effective as a stand-alone therapy for feline diabetes mellitus: the SENSATION study

Like0
Dislike0

Insights in the Development and Uses of Alternatives to Antibiotic Growth Promoters in Poultry and Swine Production

Like0
Dislike0

Undergrad researchers drive discovery in the College of Veterinary Medicine

Like0
Dislike0

Phibro Animal Health Corporation Launches Companywide Sustainable Solutions Platform; Introduces VERRATAIN™ Verified Sustainability Solutions Through Strategic VAXA Technologies Partnership

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top